ES2105992T1 - Filtracion. - Google Patents

Filtracion.

Info

Publication number
ES2105992T1
ES2105992T1 ES95923651T ES95923651T ES2105992T1 ES 2105992 T1 ES2105992 T1 ES 2105992T1 ES 95923651 T ES95923651 T ES 95923651T ES 95923651 T ES95923651 T ES 95923651T ES 2105992 T1 ES2105992 T1 ES 2105992T1
Authority
ES
Spain
Prior art keywords
filtering
sodium
virus
potassium
filtration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES95923651T
Other languages
English (en)
Other versions
ES2105992T3 (es
ES2105992T2 (es
Inventor
Stefan Winge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia and Upjohn AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26662085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2105992(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9402254A external-priority patent/SE502820C2/sv
Application filed by Pharmacia and Upjohn AB filed Critical Pharmacia and Upjohn AB
Publication of ES2105992T1 publication Critical patent/ES2105992T1/es
Publication of ES2105992T2 publication Critical patent/ES2105992T2/es
Application granted granted Critical
Publication of ES2105992T3 publication Critical patent/ES2105992T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Glass Compositions (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

LA INVENCION SE REFIERE A UN METODO DE FILTRACION VIRICA DE UNA DISOLUCION QUE CONTIENE AL MENOS UNA MACROMOLECULA Y UN CONTENIDO TOTAL DE SAL EN EL RANGO DE 0,2 M HASTA LA SATURACION DE LA DISOLUCION CON LA SAL EN CUESTION. ESTE NUEVO METODO REDUCE EL TIEMPO DE RESIDENCIA Y EL GRADO NECESARIO DE DILUCION DE LA DISOLUCION Y OPTIMIZA EL RENDIMIENTO DE LA FILTRACION VIRICA, PRINCIPALMENTE DE PROTEINAS, POLISACARIDOS Y POLIPEPTIDOS. LA REDUCCION DEL CONTENIDO DE VIRUS ES AL MENOS TAN BUENA QUE LA CONSEGUIDA CON LAS TECNICAS CONVENCIONALES CUANDO EL CONTENIDO TOTAL DE SAL ES PEQUEÑO. LA INVENCION FACILITA LA FILTRACION DE VIRUS CON LA AYUDA DE LA LLAMADA TECNICA DE "TERMINACION" ("DEADEND"), QUE CONSTA DE VARIOS PROCESOS Y OFRECE VENTAJAS ECONOMICAS EN COMPARACION CON LA TECNICA TANGENCIAL DE FILTRACION DE VIRUS UTILIZADA NORMALMENTE. CUANDO SE SOMETE EL FACTOR IX DE LAS PROTEINAS PLASMATICAS A FILTRACION VIRICA, EL RENDIMIENTO DEL PROCESO AUMENTA DE CASI EL 70 % A MAS DEL 95 % AL INCREMENTAR EL CONTENIDO DE SAL DE LA DISOLUCION SEGUN SE PROPONE EN ESTA INVENCION.
ES95923651T 1994-06-23 1995-06-22 Procedimiento de filtracion para la eliminacion de virus de una solucion acuosa contaminada con virus. Expired - Lifetime ES2105992T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9402254A SE502820C2 (sv) 1994-06-23 1994-06-23 Filtrering
SE9500724A SE9500724D0 (sv) 1994-06-23 1995-02-24 Filtrering

Publications (3)

Publication Number Publication Date
ES2105992T1 true ES2105992T1 (es) 1997-11-01
ES2105992T2 ES2105992T2 (es) 1997-11-01
ES2105992T3 ES2105992T3 (es) 2002-09-16

Family

ID=26662085

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95923651T Expired - Lifetime ES2105992T3 (es) 1994-06-23 1995-06-22 Procedimiento de filtracion para la eliminacion de virus de una solucion acuosa contaminada con virus.

Country Status (16)

Country Link
US (4) US6486306B1 (es)
EP (1) EP0796269B1 (es)
JP (1) JP3676370B2 (es)
AT (1) ATE212354T1 (es)
CA (1) CA2192683C (es)
DE (2) DE69525176T2 (es)
DK (1) DK0796269T3 (es)
ES (1) ES2105992T3 (es)
FI (1) FI965145A0 (es)
GR (1) GR970300038T1 (es)
MX (1) MX9606639A (es)
NO (1) NO320952B1 (es)
NZ (1) NZ288789A (es)
PT (1) PT796269E (es)
SE (1) SE9500724D0 (es)
WO (1) WO1996000237A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500724D0 (sv) * 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
SE9500778D0 (sv) 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
SE9603068D0 (sv) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
EP0860444A1 (en) * 1997-02-24 1998-08-26 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) Method for removing viruses from a protein solution
US6045588A (en) 1997-04-29 2000-04-04 Whirlpool Corporation Non-aqueous washing apparatus and method
US6096872A (en) * 1997-10-14 2000-08-01 Ortho Diagnostic Systems, Inc. Viral clearance process
FR2772381B1 (fr) * 1997-12-15 2001-06-08 Lab Francais Du Fractionnement Procede de preparation par filtration d'une solution de facteur viii securisee viralement
US6861001B2 (en) * 1999-12-02 2005-03-01 The General Hospital Corporation Methods for removal, purification, and concentration of viruses, and methods of therapy based thereupon
CN100507567C (zh) 2002-05-23 2009-07-01 奥索临床诊断有限公司 朊病毒蛋白的去除
CA2489123C (en) 2002-06-14 2011-03-15 Centocor, Inc. Use of a clathrate modifier to promote passage of proteins during nanofiltration
JP2004099506A (ja) * 2002-09-09 2004-04-02 Mitsubishi Rayon Co Ltd アミノ酸アミドの製造方法
WO2004089402A1 (ja) * 2003-04-09 2004-10-21 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute アルブミン製剤の製造方法
JP4558652B2 (ja) * 2003-06-20 2010-10-06 マイクロビクス・バイオシステムズ・インコーポレイテツド ウイルス生産の改善
CN100398642C (zh) * 2003-06-20 2008-07-02 迈克必斯生物系统公司 病毒生产的改进
FR2861395B1 (fr) 2003-10-23 2006-02-17 Lab Francais Du Fractionnement Facteur viii viralement securise a faible teneur en multimeres superieurs
US7695524B2 (en) 2003-10-31 2010-04-13 Whirlpool Corporation Non-aqueous washing machine and methods
US7739891B2 (en) 2003-10-31 2010-06-22 Whirlpool Corporation Fabric laundering apparatus adapted for using a select rinse fluid
EP2275432A1 (en) * 2003-12-01 2011-01-19 Novo Nordisk Health Care AG Nanofiltration of factor VII solutions to remove virus
JP2007522814A (ja) 2004-02-23 2007-08-16 クルセル ホランド ベー ヴェー ウイルスの精製方法
FR2866890B1 (fr) * 2004-02-27 2008-04-04 Lab Francais Du Fractionnement Procede de purification d'albumine comprenant une etape de nanofiltration, solution et composition a usage therapeutique la contenant
EP1740757A1 (en) 2004-04-29 2007-01-10 Unilever N.V. Dry cleaning method
US7141171B2 (en) * 2004-05-21 2006-11-28 Wisconsin Alumni Research Foundation Membrane cascade-based separation
AU2005229674B2 (en) 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
AU2006233800B2 (en) 2005-04-11 2011-07-07 Crucell Holland B.V. Virus purification using ultrafiltration
US7966684B2 (en) 2005-05-23 2011-06-28 Whirlpool Corporation Methods and apparatus to accelerate the drying of aqueous working fluids
ES2775974T3 (es) * 2006-06-26 2020-07-28 Omrix Biopharmaceuticals Inc Eliminación de virus por nanofiltración
CA2690673C (en) * 2007-06-15 2013-04-23 Amgen Inc. Methods of treating cell culture media for use in a bioreactor
KR100870423B1 (ko) * 2007-06-27 2008-11-26 주식회사 하이닉스반도체 반도체메모리소자
US7989593B1 (en) 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
US8048856B1 (en) 2010-06-23 2011-11-01 Billion King, Ltd. Treatment methods using a heat stable oxygen carrier-containing pharmaceutical composition
US7932356B1 (en) 2010-06-23 2011-04-26 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing pharmaceutical composition
US8084581B1 (en) 2011-04-29 2011-12-27 Bing Lou Wong Method for removing unmodified hemoglobin from cross-linked hemoglobin solutions including polymeric hemoglobin with a high temperature short time heat treatment apparatus
US9359397B2 (en) 2011-06-24 2016-06-07 Asahi Kasei Medical Co., Ltd. Method for manufacturing protein drug
US20130052232A1 (en) 2011-08-31 2013-02-28 Bing Lou Wong Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking
US9294158B2 (en) 2012-08-07 2016-03-22 Broadcom Corporation Broadcast audio service
KR102437202B1 (ko) 2013-08-08 2022-08-29 시에스엘 리미티드 오염 제거 방법
WO2018053384A1 (en) 2016-09-19 2018-03-22 Asgco Manufacturing, Inc. Return idler trainer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870801A (en) 1968-08-09 1975-03-11 Lever Brothers Ltd Fluid aqueous protein compositions and food products prepared therefrom
US3919044A (en) 1973-03-28 1975-11-11 Armour Pharma Processes for concentrating and purifying viruses and viral antigens
US3874999A (en) 1973-10-31 1975-04-01 American Cyanamid Co Process for the purification of virus vaccine
CA1099576A (en) 1978-03-23 1981-04-21 Chester D. Myers Improved process for isolation of proteins
US4473494A (en) 1983-05-04 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Preparation of stroma-free, non-heme protein-free hemoglobin
US4684723A (en) * 1985-09-11 1987-08-04 Miles Laboratories, Inc. Method of separating proteins from aqueous solutions
JPH0720986B2 (ja) 1985-10-07 1995-03-08 日本ケミカルリサ−チ株式会社 生理活性物質の製造法
AU605901B2 (en) * 1987-09-11 1991-01-24 Ares Trading S.A. Purification process
RU1781355C (ru) * 1990-04-23 1992-12-15 В.П.Широбоков, Л.Я.Палиенко, А.И.Евтушенко, Л.А Коптюх, Ю.В.Загороднюк и К.Д Стеценко Фильтрующий материал
US5017292A (en) 1990-05-10 1991-05-21 Millipore Corporation Membrane, process and system for isolating virus from solution
US5076933A (en) 1990-06-29 1991-12-31 Coulter Corporation Process and apparatus for removal of dna and viruses
US5221483A (en) * 1990-06-29 1993-06-22 Coulter Corporation Process and apparatus for removal of DNA, viruses and endotoxins
SE9301582D0 (sv) 1993-05-07 1993-05-07 Kabi Pharmacia Ab Purification of plasma proteins
SE9500724D0 (sv) * 1994-06-23 1995-02-24 Pharmacia Ab Filtrering

Also Published As

Publication number Publication date
DE69525176D1 (de) 2002-03-14
NO965523D0 (no) 1996-12-20
EP0796269A1 (en) 1997-09-24
ES2105992T3 (es) 2002-09-16
FI965145A (fi) 1996-12-20
DE796269T1 (de) 1998-01-02
ES2105992T2 (es) 1997-11-01
NO320952B1 (no) 2006-02-20
PT796269E (pt) 2002-06-28
US6399357B1 (en) 2002-06-04
CA2192683A1 (en) 1996-01-04
US20050203285A1 (en) 2005-09-15
MX9606639A (es) 1997-03-29
US6486306B1 (en) 2002-11-26
JPH10502074A (ja) 1998-02-24
FI965145A0 (fi) 1996-12-20
CA2192683C (en) 2005-07-05
WO1996000237A1 (en) 1996-01-04
DE69525176T2 (de) 2002-06-27
ATE212354T1 (de) 2002-02-15
NO965523L (no) 1996-12-20
SE9500724D0 (sv) 1995-02-24
GR970300038T1 (en) 1997-11-28
AU682274B2 (en) 1997-09-25
AU2813295A (en) 1996-01-19
US20030191292A1 (en) 2003-10-09
JP3676370B2 (ja) 2005-07-27
EP0796269B1 (en) 2002-01-23
NZ288789A (en) 1997-12-19
DK0796269T3 (da) 2002-05-06

Similar Documents

Publication Publication Date Title
ES2105992T2 (es) Filtracion.
FR2585044B1 (fr) Additif granulaire de detergent, procedes pour le preparer et composition detergente le contenant
DE3680271D1 (de) Thrombolytische zusammensetzung und verfahren zu deren herstellung.
ATE83686T1 (de) Zur selektiven abtrennung von metallkationen aus waessrigen loesungen geeignetes teilchenfoermiges mittel, verfahren zu seiner herstellung und seine verwendung.
YU47449B (sh) Rastvor celuloze u vodi i n-metil-morfolin-n-oksidu
SE8300320L (sv) Anvendning av en saltlosning av monoklonala antikroppar med relativt hog salthalt vid blodgruppsbestemning
NO167466C (no) Fremgangsmaate for redusering av saltinnholdet i raaolje
GB2090308B (en) Stabilized solutions of modified cellulose in brine and their use as completion and workover fluids
MY103079A (en) New ophtalmological composition of matter
ES8707502A1 (es) Procedimiento para la preparacion de -aminocarbonil-1-ben- cil-3,4-dihidro-isoquinoleinas
LU81242A1 (fr) Composition en vue de reduire le taux de phenylalanine dans le sang,et son procede d'utilisation
AU589970B2 (en) Animal litter and process for the production thereof
GR860329B (en) Reagent for the dosage of antibodies against bacteric toxines by hemaglutination method for preparation and application thereof
ES2039467T3 (es) Composicion farmaceutica que consiste en una suspension de carbonato de calcio.
ATE25107T1 (de) Verfahren zur herstellung von seifenpulver.
Hodgkinson Solubility of calcium oxalate in human urine, simulated urine, and water
ATA26182A (de) Verfahren zur herstellung des neuen 17, 18 dehydroapovincaminol - 3',4',5' trimethoxybenzoats und seiner saeureadditionssalze
IL73478A0 (en) 2-(3-pyridyl)-2-phenylamino-acetic acid derivatives,their preparation and their use as antifungals in agriculture
ES520556A0 (es) Metodo de reduccion de la concentracion en calcio de las soluciones acuosas que contienen calcio.
KR870002255A (ko) 인삼 재생 작물의 제조방법
ES8404377A1 (es) Un metodo de disminuir la perdida de fluido de salmueras pesadas.
JPS55118364A (en) Method of desalting and seasoning japanese pickled plum
HU209389B (en) Method for producing tetrasodium salt of 1,4,10,13-tetraoxa-7,16-diaza-cyclooctadecane-n,n'-dimalonic acid with sodium bromide content and one for producing medical preparatives containing said compound
ATE31623T1 (de) Injizierbare zusammensetzungen von bbm-928a.
JPS57174052A (en) Processing of fish spawn food for storage

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 796269

Country of ref document: ES